SEC Company Response from IGC Pharma, Inc. (IGC) (CIK 0001326205) (IGC) — Feb 10, 2014
IGC Pharma, Inc. (IGC) (CIK 0001326205)
Date: Feb. 10, 2014 · CIK: 0001326205 · Accession: 0001185185-14-000282
AI Filing Summary & Sentiment
Reasoning
Letter
VIA EDGAR Securities and Exchange Commission Office of Beverages, Apparel and Mining Form 10-K for the Year Ended March 31, 2013 Filed July 16, 2013 Form 8-K Filed July 1, 2013 File No. 1-32830
Dear Ms. Jenkins:
On Friday February 7, 2014 we spoke with the Staff and we were granted an extension to February 24, 2014 for the filing of our response to the referenced comments.
We are grateful for the Commission’s quick response and discussions over the phone. While we are a very small company, I can assure you that we are striving to ensure compliance and disclosures that are consistent with best practices of larger filers.
Sincerely,
ss:
Show Raw Text
CORRESP
1
filename1.htm
indiaglobal-corresp021014.htm
India Globalization Capital, Inc.
4336 Montgomery Avenue
Bethesda, Maryland 20814
Phone: 301-983-0998
Fax: 240-465-0273
February 10, 2014
VIA EDGAR
Securities and Exchange Commission
100 F. Street, N.E.
Washington, D.C. 20549
Attn: Ms. Tia Jenkins
Senior Assistant Chief Accountant
Office of Beverages, Apparel and Mining
Re:
India Globalization Capital, Inc.
Form 10-K for the Year Ended
March 31, 2013 Filed July 16, 2013
Form 8-K Filed July 1, 2013
File No. 1-32830
Dear Ms. Jenkins:
On Friday February 7, 2014 we spoke with the Staff and we were granted an extension to February 24, 2014 for the filing of our response to the referenced comments.
We are grateful for the Commission’s quick response and discussions over the phone. While we are a very small company, I can assure you that we are striving to ensure compliance and disclosures that are consistent with best practices of larger filers.
Sincerely,
ss:
India Globalization Capital, Inc.
Ram Mukunda,
Chief Executive Office